MorphoSys AG / MorphoSys to Present at Upcoming Investor Conferences . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: Commerzbank Sector Conference 2016 Date: August 30, 2016 Venue: Frankfurt, Germany Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG; Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR Goldman Sachs Annual Biotech Symposium Date: September 9, 2016 Venue: London, UK Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG; Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR Morgan Stanley Global Healthcare Conference Date: September 12-14, 2016 Venue: New York, NY, USA Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG; Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR J.P. Morgan London Small/Mid Cap Conference Date: September 13, 2016 Venue: London, UK Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG Bank of America Merrill Lynch Global Healthcare Conference 2016 Date: September 15, 2016, 4:10 pm BST (11:10 am EDT, 5:10 pm CEST) Venue: London, UK Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG; Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR Fifth Berenberg and Goldman Sachs Annual German Corporate Conference Date: September 20, 2016, 4:30 pm CEST (3:30 pm BST, 10:30 am EDT) Venue: Munich, Germany Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG; Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG Baader Investment Conference Date: September 22, 2016, 8:00 am CEST (7:00 pm BST, 2:00 am EDT) Venue: Munich, Germany Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG; Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & IR A PDF version of the presentations will be provided at www.morphosys.com. The link to webcasts will be filed under www.morphosys.com/conference-calls. About MorphoSys MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline http://www.morphosys.com/pipeline of more than 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com. HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Jochen Orlowski Associate Director Corporate Communications & IR Alexandra Goller Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-404 investors@morphosys.com Conference Announcement (PDF): http://hugin.info/130295/R/2037845/759368.pdf This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: MorphoSys AG via Globenewswire --- End of Message --- MorphoSys AG Lena-Christ-Str. 48 Martinsried / Munich Germany WKN: 663200;ISIN: DE0006632003;Index:TECH All Share,CDAX,Prime All Share, TecDAX,HDAX,MIDCAP; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse; http://www.morphosys.com
(END) Dow Jones Newswires
August 29, 2016 09:00 ET (13:00 GMT)
